We are live on
!
Find out more
PCM
Perkins Capital Management Portfolio holdings
AUM
$133M
1-Year Est. Return
127.86%
This Fund
S&P 500
This Quarter
Est. Return
-6.83%
1 Year Est. Return
+127.86%
3 Year Est. Return
+303.11%
5 Year Est. Return
+333.48%
10 Year Est. Return
–
AUM
$116M
AUM Growth
-$26.7M
(-19%)
Cap. Flow
-$11M
Cap. Flow
% of AUM
-9.44%
Top 10 Holdings %
Top 10 Hldgs %
31.93%
Holding
117
New
6
Increased
16
Reduced
64
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HTGM
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
|
+$1.97M |
| 2 |
Exagen
XGN
|
+$1.41M |
| 3 |
BioLife Solutions
BLFS
|
+$1.1M |
| 4 |
AVGR
Avinger, Inc. Common Stock
AVGR
|
+$1.08M |
| 5 |
Castle Biosciences
CSTL
|
+$619K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Magnite
MGNI
|
+$2.1M |
| 2 |
Digital Turbine
APPS
|
+$1.92M |
| 3 |
CryoPort
CYRX
|
+$1.22M |
| 4 |
Expeditors International
EXPD
|
+$797K |
| 5 |
Veracyte
VCYT
|
+$565K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 62.15% |
| 2 | Technology | 13.69% |
| 3 | Communication Services | 6.62% |
| 4 | Industrials | 5.98% |
| 5 | Consumer Staples | 2.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HTGM
26
DELISTED
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
| $1.56M | 1.35% |
13,073
+9,781
| +297% | +$1.97M |
|
|
TEUM
27
DELISTED
Pareteum Corporation
TEUM
| $1.52M | 1.31% |
1,175,548
-134,383
| -10% | -$353K |
|
28
Aflac
AFL
$64.8B
| $1.44M | 1.24% |
27,450
-3,250
| -11% | -$172K |
|
|
FPAY
29
DELISTED
FlexShopper
FPAY
| $1.39M | 1.2% |
903,100
-4,500
| -0.5% | -$7.21K |
|
30
AtriCure
ATRC
$2.04B
| $1.37M | 1.18% |
55,000
-5,750
| -9% | -$164K |
|
|
31
Exagen
XGN
$113M
| $1.35M | 1.17% |
+87,450
| New | +$1.41M |
|
32
Apyx Medical
APYX
$173M
| $1.35M | 1.16% |
199,540
-54,500
| -21% | -$387K |
|
33
AbbVie
ABBV
$455B
| $1.29M | 1.11% |
16,988
+6,038
| +55% | +$414K |
|
34
Boston Scientific
BSX
$68.4B
| $1.2M | 1.03% |
29,516
-334
| -1% | -$14.2K |
|
|
CEMI
35
DELISTED
Chembio diagnostics, Inc.
CEMI
| $1.18M | 1.02% |
193,300
-50,000
| -21% | -$298K |
|
|
PFIE
36
DELISTED
Profire Energy, Inc
PFIE
| $1.15M | 0.99% |
608,050
+65,000
| +12% | +$99.1K |
|
37
Tactile Systems Technology
TCMD
$636M
| $1.13M | 0.97% |
26,624
-4,400
| -14% | -$227K |
|
|
CGRN
38
DELISTED
Capstone Green Energy Corporation Common Stock
CGRN
| $1.12M | 0.96% |
218,990
+81,800
| +60% | +$535K |
|
39
LifeVantage
LFVN
$79.4M
| $1.1M | 0.95% |
80,168
-1,757
| -2% | -$21.4K |
|
40
Veritone
VERI
$97.6M
| $1.08M | 0.93% |
302,783
-68,667
| -18% | -$393K |
|
41
Standard BioTools
LAB
$351M
| $1.07M | 0.93% |
232,283
-65,517
| -22% | -$516K |
|
42
Verizon
VZ
$193B
| $1.05M | 0.9% |
17,334
+484
| +3% | +$27.9K |
|
43
The Joint Corp
JYNT
$119M
| $1.04M | 0.9% |
56,050
-1,250
| -2% | -$23.1K |
|
|
VG
44
DELISTED
Vonage Holdings Corporation
VG
| $1.02M | 0.88% |
90,575
| – | – |
|
|
ATRS
45
DELISTED
Antares Pharma, Inc.
ATRS
| $1.01M | 0.87% |
302,633
-72,367
| -19% | -$238K |
|
46
Merck
MRK
$321B
| $988K | 0.85% |
12,304
+2,620
| +27% | +$210K |
|
47
CVS Health
CVS
$134B
| $962K | 0.83% |
15,250
+1,300
| +9% | +$77K |
|
48
Ciena
CIEN
$52.7B
| $951K | 0.82% |
24,250
| – | – |
|
49
Bristol-Myers Squibb
BMY
$132B
| $950K | 0.82% |
18,725
-150
| -0.8% | -$7.05K |
|
|
AKTS
50
DELISTED
Akoustis Technologies Inc
AKTS
| $824K | 0.71% |
106,350
-200
| -0.2% | -$1.31K |
|
Similar funds
SVP
PWP
BF
SFG
HWMG
FTEA
WT
BAM
Perkins Capital Management's Q3 2019 Portfolio in Review
As of Q3 2019, Perkins Capital Management held 117 positions worth $116M, down 19% from $143M the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Perkins Capital Management withdrew a net $11M in Q3 2019, closing 5 positions and reducing 64 holdings. Its most notable exit was Expeditors International, an estimated $797K position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 62% of assets, up from 60% a quarter earlier, followed by Technology and Communication Services.
Against the trend, Perkins Capital Management opened a new position in Exagen worth $1.35M.
- Perkins Capital Management's largest Q3 2019 buy was Exagen: 87,450 shares worth $1.35M.
- Perkins Capital Management added most to HTG Molecular Diagnostics, Inc. Common Stock in Q3 2019, an estimated $1.97M increase.
- Perkins Capital Management's biggest Q3 2019 reduction was Magnite, cutting an estimated $2.1M.
- Perkins Capital Management fully exited Expeditors International in Q3 2019, selling an estimated $797K.
- Perkins Capital Management's ten largest holdings make up 32% of its $116M portfolio in Q3 2019.
- Perkins Capital Management opened 6 new positions and closed 5 in Q3 2019.
- Perkins Capital Management's portfolio value fell 19% quarter-over-quarter to $116M.
Based on Perkins Capital Management's 13F filing for Q3 2019, filed 23 Oct 2019.